Question
MRONJのリスク因子は何ですか？
Answer
さまざまな局所的因子と全身的因子があり、そのすべてが重要です。
MRONJのリスク因子1)～9)
| 薬剤関連因子 |
|
| 局所因子 | |
| 全身因子 |
|
| その他の因子 |
|
1)Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg 2014; 72(10): 1938-1956.
2)Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015; 30(1): 3-23.
3)Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 2017; 35(1): 6-19.
4)King R, Tanna N, Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review. Oral Surg Oral Med Oral Pathol Oral Radiol 2019; 127(4): 289-299,
5)Wan JT, Sheeley DM, Somerman MJ, Lee JS, Mitigating osteonecrosis of the jaw(ONJ) through preventive dental care and understanding of risk factors. Bone Res 2020; 8: 14.
6)Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Schiødt M, Klinge B. The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis. Clin Oral Implants Res 2018; 29 Suppl 18: 54-92.
7)Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw(BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 2015; 44(5): 568-585.
8) 顎骨壊死検討委員会. 骨吸収抑制薬関連顎骨壊死の病態と管理：顎骨壊死検討委員会ポジションペーパー 2016. (https://www.jsoms.or.jp/medical/wp-content/uploads/2015/08/position_paper2016.pdf)
9)Nocolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, Epstein JB, Elad S, Campisi G, Tsoukalas N, Bektas-Kayhan K, Tan W, Body JJ, Migliorati C, Lalla RV; MASCC Bone Study Group. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer 2019; 27(2): 383-394.
※参考書籍
「MRONJのリスクがある患者の歯科治療を行う時に読む本」
著 黒嶋伸一郎、澤瀬隆、米田俊之
クインテッセンス出版株式会社
「薬剤関連顎骨壊死の病態と管理：顎骨壊死検討委員会ポジションペーパー2023」
顎骨壊死検討委員会
